AU2016348610B2 - Method for vaccination against a self-antigen in a human patient - Google Patents

Method for vaccination against a self-antigen in a human patient Download PDF

Info

Publication number
AU2016348610B2
AU2016348610B2 AU2016348610A AU2016348610A AU2016348610B2 AU 2016348610 B2 AU2016348610 B2 AU 2016348610B2 AU 2016348610 A AU2016348610 A AU 2016348610A AU 2016348610 A AU2016348610 A AU 2016348610A AU 2016348610 B2 AU2016348610 B2 AU 2016348610B2
Authority
AU
Australia
Prior art keywords
antigen
self
immune response
administration
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016348610A
Other languages
English (en)
Other versions
AU2016348610A1 (en
Inventor
Gergana Galabova
Sabine SCHMIDHUBER
Achim Schneeberger
Arne Von Bonin
Dorian WINTER
Jana Zimmermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AC Immune SA
Original Assignee
AC Immune SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AC Immune SA filed Critical AC Immune SA
Publication of AU2016348610A1 publication Critical patent/AU2016348610A1/en
Assigned to AC IMMUNE SA reassignment AC IMMUNE SA Request for Assignment Assignors: AFFIRIS AG
Application granted granted Critical
Publication of AU2016348610B2 publication Critical patent/AU2016348610B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2016348610A 2015-11-03 2016-11-02 Method for vaccination against a self-antigen in a human patient Active AU2016348610B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15192794.4 2015-11-03
EP15192794 2015-11-03
PCT/EP2016/076372 WO2017076873A1 (en) 2015-11-03 2016-11-02 Method for vaccination against a self-antigen in a human patient

Publications (2)

Publication Number Publication Date
AU2016348610A1 AU2016348610A1 (en) 2018-05-10
AU2016348610B2 true AU2016348610B2 (en) 2023-08-31

Family

ID=54396782

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016348610A Active AU2016348610B2 (en) 2015-11-03 2016-11-02 Method for vaccination against a self-antigen in a human patient

Country Status (10)

Country Link
US (1) US12290553B2 (enExample)
EP (1) EP3370761A1 (enExample)
JP (2) JP7378931B2 (enExample)
KR (1) KR102857456B1 (enExample)
CN (1) CN108472344A (enExample)
AU (1) AU2016348610B2 (enExample)
BR (1) BR112018008697A2 (enExample)
CA (1) CA3003943A1 (enExample)
RU (1) RU2734924C2 (enExample)
WO (1) WO2017076873A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102857456B1 (ko) * 2015-11-03 2025-09-08 에이씨 이뮨 에스에이 인간 환자에서 자가-항원에 대한 예방접종을 위한 방법
AR111760A1 (es) * 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
CN112533959A (zh) * 2018-05-22 2021-03-19 阿尔伯塔大学理事会 用于基于结构的淀粉样蛋白疾病疫苗和抗原的无害的、结构化的支架
CA3185563A1 (en) 2020-08-04 2022-02-10 Dorian WINTER Immunogenic compounds
KR102527616B1 (ko) 2021-03-18 2023-05-02 정성욱 항체 관련 정보를 제공하는 방법 및 디바이스
MX2024009485A (es) 2022-02-09 2024-08-14 Ac Immune Sa Vacunas terapeuticas anti-alfa-sinucleina.
WO2025172592A1 (en) 2024-02-15 2025-08-21 Ac Immune Sa Alpha synuclein therapeutic vaccine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009103105A2 (en) * 2008-02-22 2009-08-27 Affiris Ag Mimotope
WO2011009152A1 (en) * 2009-07-23 2011-01-27 Affiris Ag Vaccine
WO2014033158A2 (en) * 2012-08-29 2014-03-06 Affiris Ag Vaccine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101077416A (zh) 2002-10-23 2007-11-28 葛兰素史密丝克莱恩生物有限公司 抗疟疾的疫苗接种方法
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT508638B1 (de) 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
ES2670576T3 (es) 2009-09-03 2018-05-31 Pfizer Vaccines Llc Vacuna de PCSK9
US9408907B2 (en) 2009-12-15 2016-08-09 Glaxosmithkline Biologicals Sa Homogenous suspension of immunopotentiating compounds and uses thereof
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
DK3110439T3 (da) 2014-02-28 2019-05-13 Affiris Ag Pcsk9-vacciner
KR102857456B1 (ko) 2015-11-03 2025-09-08 에이씨 이뮨 에스에이 인간 환자에서 자가-항원에 대한 예방접종을 위한 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009103105A2 (en) * 2008-02-22 2009-08-27 Affiris Ag Mimotope
WO2011009152A1 (en) * 2009-07-23 2011-01-27 Affiris Ag Vaccine
WO2014033158A2 (en) * 2012-08-29 2014-03-06 Affiris Ag Vaccine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AFFIRIS AG: 31 July 2014 (2014-07-31), XP002757397, Retrieved from the Internet [retrieved on 20160503] *
MARKUS MANDLER, ELVIRA VALERA, EDWARD ROCKENSTEIN, HARALD WENINGER, CHRISTINA PATRICK, ANTHONY ADAME, RADMILA SANTIC, STEFANIE MEI: "Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials", ACTA NEUROPATHOLOGICA, SPRINGER VERLAG., vol. 127, no. 6, 1 June 2014 (2014-06-01), pages 861 - 879, XP055203363, ISSN: 00016322, DOI: 10.1007/s00401-014-1256-4 *
MARKUS MANDLER;ELVIRA VALERA;EDWARD ROCKENSTEIN;MICHAEL MANTE;HARALD WENINGER;CHRISTINA PATRICK;ANTHONY ADAME;SABINE SCHMIDHUBER;R: "Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy", MOLECULAR NEURODEGENERATION, BIOMED CENTRAL LTD, LO, vol. 10, no. 1, 19 March 2015 (2015-03-19), Lo , pages 10, XP021215331, ISSN: 1750-1326, DOI: 10.1186/s13024-015-0008-9 *
SIEGRIST CLAIRE-ANNE, "Section 1; Chapter 2: Vaccine Immunology", 1 January 2008, Vaccines Von Stanley A. Plotkin, Walter A. Orenstein, Philadelphia, PA.: Elsevier, Saunders, US, pages 17-36, ISBN: 978-1-4160-3611-1 *

Also Published As

Publication number Publication date
BR112018008697A2 (en) 2018-10-30
CA3003943A1 (en) 2017-05-11
US20190091306A1 (en) 2019-03-28
RU2734924C2 (ru) 2020-10-26
JP7628333B2 (ja) 2025-02-10
WO2017076873A1 (en) 2017-05-11
CN108472344A (zh) 2018-08-31
AU2016348610A1 (en) 2018-05-10
KR102857456B1 (ko) 2025-09-08
US12290553B2 (en) 2025-05-06
RU2018120009A3 (enExample) 2020-04-23
KR20180079406A (ko) 2018-07-10
RU2018120009A (ru) 2019-12-04
EP3370761A1 (en) 2018-09-12
JP7378931B2 (ja) 2023-11-14
JP2023175708A (ja) 2023-12-12
JP2018532782A (ja) 2018-11-08

Similar Documents

Publication Publication Date Title
AU2016348610B2 (en) Method for vaccination against a self-antigen in a human patient
Wang et al. UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer's disease
Ghochikyan et al. Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Aβ antibody response with Alum to Quil A adjuvant switch
US20110092436A1 (en) Compounds for treating symptoms associated with parkinson's disease
JP5559789B2 (ja) アルツハイマー病の処置のための免疫治療組成物
KR20120004994A (ko) 치료적 이용 방법
US20150093431A1 (en) Compositions
US20160008443A1 (en) METHOD FOR TREATING A beta-AMYLOIDOSIS
JP2007522119A (ja) アミロイド関連疾患用ワクチンとしてのアミロイドタンパク質のコンジュゲート
Maier et al. Modulation of the humoral and cellular immune response in Aβ immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT (R192G)
TW201345927A (zh) 組成物
JP2023536497A (ja) 免疫原性化合物
Ding et al. Active immunization with the peptide epitope vaccine Aβ3-10-KLH induces a Th2-polarized anti-Aβ antibody response and decreases amyloid plaques in APP/PS1 transgenic mice
CA3012417C (en) Amyloid conjugate and uses and methods thereof
Imran Spotlight on the Clinical Development, Inventions, and Prospects of the Alzheimer’s Disease Vaccines
EA048154B1 (ru) Иммуногенные соединения
NZ744411B2 (en) Amyloid conjugate and uses and methods thereof
HUE025186T2 (en) Methods and methods using supramolecular constructs

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: AC IMMUNE SA

Free format text: FORMER APPLICANT(S): AFFIRIS AG

FGA Letters patent sealed or granted (standard patent)